Tacton Named a Leader in the 2025 Gartner ® Magic Quadrant™ for CPQ Applications for the Third Consecutive Time
Tacton, a global leader in Configure, Price, Quote (CPQ) software and leading SaaS platform simplifying sales and configuration processes for manufacturers of complex products, today announced its recognition as a Leader in the 2025 Gartner® Magic Quadrant™ for CPQ Applications. Positioned highest for Ability to Execute, this marks Tacton’s third consecutive time as a Leader, which we believe reinforces its commitment to delivering innovative solutions for manufacturers.
Tacton’s advanced technology empowers manufacturers to address unique challenges by enhancing operational efficiency, streamlining sales processes, and delivering buyer-centric solutions. As a trusted partner, Tacton supports manufacturers in advancing sustainability, transforming sales strategies, and driving business growth.
“For five consecutive times, Tacton has been recognized in the Gartner Magic Quadrant for CPQ Applications, including being named a Leader for the past three,” said Bo Gyldenvang, Chief Executive Officer at Tacton. “We believe this reflects our strong position as the go-to platform for complex manufacturers seeking to overcome industry challenges with innovative and scalable solutions. Manufacturers can rely on Tacton to streamline operations, optimize buyer engagement, and stay ahead in a competitive market.”
A Gartner Magic Quadrant is a culmination of research in a specific market, giving you a wide-angle view of the relative positions of the market’s competitors. By applying a graphical treatment and a uniform set of evaluation criteria, a Magic Quadrant helps you quickly ascertain how well technology providers are executing their stated visions and how well they are performing against Gartner’s market view.
For Tacton, this announcement is the latest in a series of milestones. In addition to its placement in the Gartner Magic Quadrant, the company was named a Major Player in IDC’s MarketScape for APQ Applications 2024–2025 and secured placement in MGI Research’s CPQ Buyer’s Guide as the number one CPQ product. These achievements highlight Tacton’s continued leadership and commitment to innovation in the CPQ market.
Access a complimentary copy of the Gartner report and learn more about Tacton at www.tacton.com
Gartner Disclaimer
This graphic was published by Gartner, Inc. as part of a larger research document and should be evaluated in the context of the entire document. The Gartner document is available upon request from Tacton.
Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, Magic Quadrant is a registered trademark of Gartner, Inc. and/or its affiliates and is used herein with permission. All rights reserved.
Gartner, Magic Quadrant for Configure, Price and Quote Applications, By Mark Lewis, Luke Tipping, 22 January 2025.
About Tacton
Tacton is a leading SaaS company redefining how manufacturers of complex products engage with their buyers. Its cutting-edge buyer engagement platform empowers manufacturers to streamline the buyer journey, deliver personalized, customer-centric experiences, and bring complex products to market faster and more efficiently.
Tacton partners with manufacturers to drive smart factory initiatives and align operations with customer needs. With over 25 years of experience and trusted by more than 100 global leaders like ABB, Daimler, MAN, Scania, Siemens, Xylem, and Yaskawa, Tacton is co-headquartered in Chicago and Stockholm, with regional offices in Karlsruhe, Warsaw, and Tokyo. Learn more at www.tacton.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250129645781/en/
Contacts
Lori McInerney
SVP Global Marketing, Tacton
Lori.McInerney@tacton.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Coincheck Group N.V. to Announce Third Quarter 2025 Results on February 12, 202531.1.2025 15:30:00 EET | Press release
Coincheck Group N.V. (the “Company”) (Nasdaq: CNCK), the holding company for Coincheck, Inc, a leading Japanese crypto exchange, today announced that the Company will release its third quarter 2025 financial results on Wednesday, February 12, 2025. The Company will host a conference call to discuss third quarter 2025 financial results at 5:00 pm ET that same day. Hosting the call will be Oki Matsumoto, Executive Chairman, Gary Simanson, Chief Executive Officer, and Jason Sandberg, Chief Financial Officer. The call will be webcast live from the Company's website at www.coincheckgroup.com. A replay will be available on the Company’s investor relations website following the call. The conference call can also be accessed over the phone by dialing (877) 407-4018 or (201) 689-8471; the Conference ID is 13751285. About Coincheck Group N.V. Headquartered in the Netherlands, Coincheck Group N.V. (NASDAQ: CNCK) is a public limited liability company and the holding company for Coincheck, Inc. Coi
Datopotamab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer31.1.2025 15:00:00 EET | Press release
Datopotamab deruxtecan (Dato-DXd) has been recommended for approval in the European Union (EU) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine therapy and at least one line of chemotherapy in the advanced setting. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE:45680) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast01 phase 3 trial published in the Journal of Clinical Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast01, datopot
REPLY: Coding and Cybersecurity, Registration Is Now Open for the Reply Hack The Code Challenge 202531.1.2025 13:42:00 EET | Press release
Reply has announced the opening of registrations for the ReplyHackThe Code Challenge 2025, the leading online team coding competition, which will take place on March 12th 2025. This year's challenge will combine programming and cybersecurity for the first time, offering participants the opportunity to tackle algorithmic problems and cybersecurity challenges. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250131992792/en/ Reply has announced the opening of registrations for the Reply Hack The Code Challenge 2025, the leading online team coding competition, which will take place on March 12th 2025. This year's challenge will combine programming and cybersecurity for the first time, offering participants the opportunity to tackle algorithmic problems and cybersecurity challenges. (Photo: Business Wire) The competition follows the format of previous events, with two parallel challenges: the Standard Edition, aimed at university
GE HealthCare Invests $138 Million in Cork, Ireland Manufacturing Facility to Address Increasing Contrast Media Demand31.1.2025 10:00:00 EET | Press release
GE HealthCare (Nasdaq: GEHC) today announced a $138 million investment to expand its Carrigtohill, Cork contrast media fill and finish manufacturing site in Ireland. A new state-of-the-art facility on the grounds of the existing site will enable 25 million more patient doses per year of contrast media by the end of 2027, helping address growing global demand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250130241464/en/ GE HealthCare’s contrast media manufacturing site in Cork (Photo: Business Wire) Contrast media are injectable diagnostic imaging agents used to enhance visualization of organs, blood vessels and tissues during medical imaging. Global demand for iodine-based contrast media, used in X-Ray, Computed Tomography (CT) and Interventional procedures is expected to double in the next decade, driven by ageing populations and the increasing global prevalence of chronic disorders. In 2024, the Carrigtohill facility, a
Vertex Announces CASGEVY ® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England31.1.2025 09:00:00 EET | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). The reimbursement agreement comes as the National Institute for Health and Care Excellence (NICE) issues positive guidance recommending CASGEVY’s use in the NHS. It means that eligible SCD patients in England now have access to the therapy following the prior agreement for transfusion-dependent beta thalassemia (TDT) patients announced last August. “Today is an important day for the sickle cell community who have gone too long without treatments that address the underlying cause of their devastating disease,” said Ludovic Fenaux, Senior Vice President, Vertex International. “We are pleased to have reached this new agreement that ensures both eligible SCD and TDT patients can now be treated with CASGEVY, recognizing the value a one-time treatment can provide to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom